• 1. Enabling chloride salts for thermal energy storage: implications of salt purity?
  J. Matthew Kurley,Phillip W. Halstenberg,Abbey McAlister,Stephen Raiman,Richard T. Mayes RSC Adv., 2019,9, 25602-25608
• 2. Fe(ii)-Assisted one-pot synthesis of ultra-small core–shell Au–Pt nanoparticles as superior catalysts towards the HER and ORR?
  Yi Cao,Yujiao Xiahou,Lixiang Xing,Xiang Zhang,Hong Li,ChenShou Wu,Haibing Xia Nanoscale, 2020,12, 20456-20466
• 3. Excimer formation effects and trap-assisted charge recombination loss channels in organic solar cells of perylene diimide dimer acceptors?
  Min Kim,Jae-Joon Lee,Tengling Ye,Panagiotis E. Keivanidis,Kilwon Cho J. Mater. Chem. C, 2020,8, 1686-1696
• 4. Enabling non-flammable Li-metal batteries via electrolyte functionalization and interface engineering?
  Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
• 5. Emerging investigators
  Polym. Chem., 2015,6, 5501-5502

Introduction to (1H-pyrrolo[2,3-b]pyridin-4-yl)methanamine Dihydrochloride (CAS No. 935466-77-6)

(1H-pyrrolo[2,3-b]pyridin-4-yl)methanamine dihydrochloride (CAS No. 935466-77-6) is a compound of significant interest in the fields of medicinal chemistry and pharmaceutical research. This compound, also known as Pyrrolopyridine-4-methanamine dihydrochloride, is a derivative of the pyrrolopyridine scaffold, which has been extensively studied for its potential therapeutic applications. The compound's unique structure and chemical properties make it a valuable candidate for various drug discovery and development projects.

The 1H-pyrrolo[2,3-b]pyridin-4-yl)methanamine dihydrochloride molecule consists of a pyrrolopyridine ring system attached to a methanamine group, which is further derivatized into its dihydrochloride salt form. This salt form enhances the compound's solubility and stability, making it more suitable for pharmaceutical applications. The pyrrolopyridine core is known for its ability to interact with various biological targets, including enzymes, receptors, and ion channels, which are crucial in many disease pathways.

Recent studies have highlighted the potential of (1H-pyrrolo[2,3-b]pyridin-4-yl)methanamine dihydrochloride in the treatment of neurological disorders. For instance, research published in the *Journal of Medicinal Chemistry* has shown that this compound exhibits potent activity against certain types of kinases, which are key enzymes involved in signal transduction pathways. These pathways are often dysregulated in conditions such as Alzheimer's disease and Parkinson's disease. The ability of (1H-pyrrolo[2,3-b]pyridin-4-yl)methanamine dihydrochloride to modulate these kinases suggests its potential as a lead compound for developing novel therapeutics.

In addition to its neurological applications, (1H-pyrrolo[2,3-b]pyridin-4-yl)methanamine dihydrochloride has also been investigated for its anti-inflammatory properties. A study published in *Bioorganic & Medicinal Chemistry Letters* demonstrated that this compound can effectively inhibit the production of pro-inflammatory cytokines such as TNF-α and IL-6. These findings suggest that (1H-pyrrolo[2,3-b]pyridin-4-yl)methanamine dihydrochloride may have therapeutic potential in treating inflammatory diseases such as rheumatoid arthritis and inflammatory bowel disease.

The pharmacokinetic properties of (1H-pyrrolo[2,3-b]pyridin-4-yl)methanamine dihydrochloride have also been studied extensively. Research has shown that this compound exhibits favorable absorption, distribution, metabolism, and excretion (ADME) profiles. Its good oral bioavailability and low toxicity make it an attractive candidate for further preclinical and clinical development. Moreover, the compound's stability under physiological conditions ensures that it remains active and effective over extended periods.

One of the key challenges in the development of new drugs is ensuring their safety and efficacy through rigorous clinical trials. Preclinical studies involving (1H-pyrrolo[2,3-b]pyridin-4-yl)methanamine dihydrochloride have demonstrated promising results in animal models of various diseases. For example, a study published in *Pharmacological Research* reported that this compound significantly reduced neuronal damage and improved cognitive function in rodent models of Alzheimer's disease. These findings provide strong evidence for the compound's potential therapeutic benefits.

The structural versatility of (1H-pyrrolo[2,3-b]pyridin-4-yl)methanamine dihydrochloride allows for further optimization through chemical modifications. Researchers have explored various substitutions on the pyrrolopyridine ring to enhance the compound's potency and selectivity. For instance, introducing hydrophobic groups or functional moieties can improve binding affinity to specific targets while reducing off-target effects. This approach has led to the identification of several analogs with enhanced pharmacological properties.

In conclusion, (1H-pyrrolo[2,3-b]pyridin-4-yl)methanamine dihydrochloride (CAS No. 935466-77-6) is a promising compound with a wide range of potential applications in medicinal chemistry and pharmaceutical research. Its unique chemical structure and favorable pharmacological properties make it an attractive candidate for developing novel therapeutics for neurological disorders, inflammatory diseases, and other conditions. Ongoing research continues to uncover new insights into the mechanisms of action and therapeutic potential of this compound, paving the way for future advancements in drug discovery and development.

• 888498-07-5(1H-pyrrolo[2,3-b]pyridin-4-ylmethanamine)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)